LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent

OncoImmunology

Volumn 3, Issue 6, 2014, Pages

  Camilio, Ketil André ^a,b   Rekdal, Øystein ^a   Sveinbjörnsson, Baldur ^a,b  

^a LYTIX BIOPHARMA AS   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Anticancer peptides; B16 melanoma; DAMPs; Immunogenic cell death; Inflammation; Intralesional treatment

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; LTX 315; ONCOPORE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; MELANOMA; MOLECULAR DYNAMICS; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION;

EID: 84906509684     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.29181     Document Type: Article

References (10)

1. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415:389-95; PMID:11807545; http://dx.doi. org/10.1038/415389a
2. Wieczorek M, Jenssen H, Kindrachuk J, Scott WR, Elliott M, Hilpert K, Cheng JT, Hancock RE, Straus SK. Structural studies of a peptide with immune modulating and direct antimicrobial activity. Chem Biol 2010; 17:970-80; PMID:20851346; http:// dx.doi.org/10.1016/j.chembiol.2010.07.007
3. Schweizer F. Cationic amphiphilic peptides with cancer-selective toxicity. Eur J Pharmacol 2009; 625:190-4; PMID:19835863; http://dx.doi.org/10.1016/j. ejphar.2009.08.043
4. Mader JS, Salsman J, Conrad DM, Hoskin DW. Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol Cancer Ther 2005; 4:612-24; PMID:15827335; http://dx.doi.org/10.1158/1535-7163.MCT-04-0077
5. Naumov GN, Townson JL, MacDonald IC, Wilson SM, Bramwell VH, Groom AC, Chambers AF. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or latedeveloping metastases. Breast Cancer Res Treat 2003; 82:199-206; PMID:14703067; http://dx.doi. org/10.1023/B:BREA.0000004377.12288.3c
6. Eliassen LT, Berge G, Leknessund A, Wikman M, Lindin I, Løkke C, Ponthan F, Johnsen JI, Sveinbjørnsson B, Kogner P, et al. The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. Int J Cancer 2006; 119:493-500; PMID:16572423; http://dx.doi.org/10.1002/ijc.21886
7. Eliassen LT, Berge G, Sveinbjørnsson B, Svendsen JS, Vorland LH, Rekdal Ø. Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anticancer Res 2002; 22:2703-10; PMID:12529985
8. Camilio KA, Berge G, Ravuri CS, Rekdal O, Sveinbjørnsson B. Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315. Cancer Immunol Immunother 2014; 63:601-13; PMID:24676901; http://dx.doi.org/10.1007/s00262-014-1540-0
9. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; http://dx.doi.org/10.1146/ annurev-immunol-032712-100008
10. Berge G, Eliassen LT, Camilio KA, Bartnes K, Sveinbjørnsson B, Rekdal O. Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide. Cancer Immunol Immunother 2010; 59:1285-94; PMID:20422410; http://dx.doi.org/10.1007/s00262-010-0857-6